Breast Cancer โ Letโs Make It Personal: Agendia Supports Breast Cancer Awareness Month with International Program of Activities
Flash Mob for Breast Cancer Empowerment, in partnership with the Read More
10-Year Prospective Outcome Data and MINDACT Sub-Study Presented at ESMO Congress Demonstrate Prognostic Value of MammaPrint in Personalizing Early-Stage Breast Cancer Treatment
First time 10-year prospective outcome data confirms clinical utility of Read More
Agendiaโs MammaPrint Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data
ASCOยฎ recommends MammaPrintยฎ for clinical high risk, hormone receptor-positive, HER2-negative Read More
Agendiaโs MammaPrint recommended by the 2017 St. Gallen International Breast Cancer Guidelines in significant update
IRVINE, CA and AMSTERDAM โ 6 July 2017 - Agendia, Read More
MammaPrint Late Recurrence (20yr) Low Risk result identifies breast cancer patients with 97% survival at 20-years with limited endocrine therapy treatment
Retrospective analysis of patient samples from the prospective, randomized Stockholm Read More
Three New Studies Presented at ASCO Annual Meeting Demonstrate Benefits of MammaPrint in Aiding Individualized Treatment Management for Early-Stage Breast Cancer Patients
A multi-center trial demonstrated that MammaPrint identified 30% more low Read More
Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics
Agreement Accelerates the Development of Tests to Help Assess Risk Read More
Agendiaโs MammaPrint Now Included in Blue Shield of California Coverage for Breast Cancer Patients
IRVINE, CA and AMSTERDAM โ 1 June 2017 โ Agendia, Read More
Agendiaโs MammaPrint Now Included in First Coast Coverage for Medicare Breast Cancer Patients in Florida, Puerto Rico and the Virgin Islands
IRVINE, CA and AMSTERDAM โ 2 May 2017 โ Agendia, Read More
Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman
IRVINE, CA and AMSTERDAM โ 12 April 2017 โ Agendia, Read More
